Plasma n6 polyunsaturated fatty acid levels and risk for total and cause-specific mortality: A prospective observational study from the UK Biobank

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Harris, William S.
• dc.contributor.author Westra, Jason
• dc.contributor.author Tintle, Nathan
• dc.contributor.author Sala Vila, Aleix
• dc.contributor.author Wu, Jason Hy
• dc.contributor.author Marklund, Matti
• dc.date.accessioned 2025-07-25T12:26:50Z
• dc.date.embargoEnd info:eu-repo/date/embargoEnd/2025-10-01
• dc.date.issued 2024
• dc.description.abstract Background: The potential role of n-6 PUFAs in major health outcomes remains controversial. Objectives: To examine the relationship between the major plasma n6 PUFA, linoleic acid (LA), as well as the non-LA n6 PUFAs, and total and cause-specific mortality. Methods: This was a prospective, observational, biomarker-based study in the UK Biobank. Individuals with complete information on baseline demographic, covariate and plasma PUFA levels (percent ot total fatty acids) and mortality outcomes were included (n=257,925). Multivariable-adjusted, Cox-proportional hazards models were used to predict risk of death from all-causes, and from cardiovascular disease (CVD), cancer, and other causes as a function of plasma LA and non-LA n6 levels, both continuously and by PUFA quintile (Q). Results: Comparing LA Q5 to Q1, the hazard ratio (HR, 95% CI) for total mortality was 0.80 (0.76, 0.84; p<0.001), and this was similar for all three cause-specific death categories. On the other hand, mortality HR for non-LA n6 was 1.12 (1.08,1.17; p<0.001), and this was primarily due to increased risk for non-CVD, noncancer deaths [HR 1.29 (1.19,1.40; p<0.001)]. Exploratory analyses among the eight next most common other causes of death suggested that both the decreased risk associated with higher LA and the increased risk associated with non-LA n6 were confined to deaths from respiratory and digestive diseases. Conclusions: These findings highlight the profound differences in mortality risk related to LA and non-LA n6 PUFA levels and underscore the inappropriateness of treating n-6 PUFAs as a homogenous class with respect to health outcomes. They also support recommendations to maintain (if not increase) current LA intakes.
• dc.embargo.liftdate 2025-10-01
• dc.format.mimetype application/pdf
• dc.identifier.citation Harris WS, Westra J, Tintle NL, Sala-Vila A, Wu JH, Marklund M. Plasma n6 polyunsaturated fatty acid levels and risk for total and cause-specific mortality: A prospective observational study from the UK Biobank. Am J Clin Nutr. 2024 Oct;120(4):936-42. DOI: 10.1016/j.ajcnut.2024.08.020
• dc.identifier.doi http://dx.doi.org/10.1016/j.ajcnut.2024.08.020
• dc.identifier.issn 0002-9165
• dc.identifier.uri http://hdl.handle.net/10230/71004
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Am J Clin Nutr. 2024 Oct;120(4):936-42
• dc.rights © Elsevier http://dx.doi.org/10.1016/j.ajcnut.2024.08.020
• dc.rights.accessRights info:eu-repo/semantics/embargoedAccess
• dc.subject.keyword Biomarkers
• dc.subject.keyword Cancer
• dc.subject.keyword Cardiovascular disease
• dc.subject.keyword Essential fatty acids
• dc.subject.keyword Linoleic acid
• dc.subject.keyword Longevity
• dc.subject.keyword Mortality
• dc.title Plasma n6 polyunsaturated fatty acid levels and risk for total and cause-specific mortality: A prospective observational study from the UK Biobank
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion